In the randomized, double-blind, phase 3 study, experts explored treatment with neoadjuvant pembrolizumab (Keytruda) plus chemotherapy, followed by adjuvant pembrolizumab, in patients aged 18 years ...

The KEYNOTE-689 study evaluating pembrolizumab in this patient population met its primary end point of event-free survival.

First targeted treatment to reduce the risk of ALK positive lung cancer returning after complete tumour removal recommended by NICE ...

For patients with early-stage triple-negative breast cancer, neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab yields a significant improvement in overall survival ...

Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in ...

BARCELONA, Spain — Adding pembrolizumab to standard concurrent chemoradiotherapy (CCRT) significantly improves overall survival in patients with high-risk, locally advanced cervical cancer ...

This emphasizes a critical issue as pembrolizumab is increasingly being used in early TNBC and could have long-term survivorship implications. Supported in part by The University of Texas MD Anderson ...

After a median follow-up of 75 months, the 5-year OS was 86.6% in patients who received pembrolizumab (Keytruda) before and after surgery compared with 81.7% in those who received only neoadjuvant ...

The imaging agent Gleolan is only approved for glioma surgery, so the current trial could lead to a new indication. In this ...

ABL Bio (CEO Sang Hoon Lee), a company specializing in bispecific antibodies, today announced that it has entered into a ...